Screener
Stoke Therapeutics, Inc. STOK Other External Program Costs — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| ADOA(1) | 1,859 | 1,201 |
| SYNGAP1(1) | 745 | 342 |
| MECP2(1) | — | 147 |
| Other external program costs | 3,178 | 1,829 |
| Payroll and other personnel costs - R&D (2) | 16,118 | 11,012 |
| Payroll and other personnel costs - SG&A (2) | 11,057 | 8,929 |
| Other non-program costs - R&D (3) | 1,680 | 1,407 |
| Other non-program costs - SG&A (3) | 5,156 | 4,788 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s other external program costs — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported other external program costs — operating expenses of -$3.18M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other external program costs — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s other external program costs — operating expenses decreased by 73.8% year-over-year, from -$1.83M to -$3.18M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other external program costs — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s other external program costs — operating expenses has grown at a -5.3% compound annual growth rate (CAGR), from -$9.85M to -$8.84M.
- What does other external program costs — operating expenses mean?
- This metric represents the aggregate operating expenses allocated to secondary or non-core research and development programs outside of the company's primary clinical pipeline. It captures the costs associated with early-stage discovery efforts, exploratory research, or ancillary projects that do not yet meet the criteria for primary program reporting. Monitoring these costs helps investors assess the company's investment in long-term pipeline diversification and the efficiency of its secondary research initiatives.
Ask your AI about Stoke Therapeutics, Inc.'s other external program costs — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude